Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis
Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443), a biopharmaceutical company based in China, has submitted...
Auto-immune
BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market
US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...
JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...
AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial
AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...
RemeGen’s Telitacicept Secures FDA Approval for Global Phase III Study in Primary Sjogren’s Syndrome
RemeGen (HKG: 9995), a China-based pharmaceutical company, has received approval from the US Food and...
Lynk Pharmaceuticals Initiates Phase III Clinical Trial for Rheumatoid Arthritis Drug in China
China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in...
InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and...
BMS Broadens Scope of IMID Collaboration, Aiming for Deeper Insights into Sjögren’s and Atopic Dermatitis
Bristol Myers Squibb (BMS; NYSE: BMY) has expanded its 2016 partnership with IMIDomics, broadening the...
J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth
Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline,...
Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the...
Everest Medicines Secures IND Review for Zetomipzomib in China
Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for zetomipzomib...
Akeso’s AK111 Achieves Key Efficacy Milestones in Phase III Trial for Plaque Psoriasis
Akeso Biopharma (HKG: 9926), based in China, has announced that its pivotal Phase III clinical...
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of...
Everest Medicines Reports Positive Phase III Results for Velsipity in Ulcerative Colitis
Everest Medicines (HKG: 1952), based in China, has announced positive topline results from a multi-center...
Everest Medicines’ Nefecon NDA for IgAN Accepted for Review in South Korea
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the New Drug Application...
Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus
Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...
Everest Medicines’ Nefecon for IgAN Receives NMPA Approval in China
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that its New Drug Application...
RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete...
Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen
Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...